drugset / Trial / NCT07229586
A Study of SHR-7367 With Anti-tumor Agents in Patients With Solid Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study aims to evaluate the safety and preliminary efficacy of SHR-7367 in combination with antineoplastic agents in subjects with advanced solid tumors, and to determine the maximum tolerated dose (MTD) and the recommended Phase II dose (RP2D).
Timeline
- Start
- 2025-12-02
- Primary completion
- 2027-12
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adebrelimab | Monoclonal antibody | — | — |
| Subject | Gemcitabine | Small molecule | — | — |
| Subject | Paclitaxel | Small molecule | — | — |
| Subject | SHR-7367 | Unknown | — | — |